| Code | CSB-RA707478MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Feladilimab, targeting the Inducible T-cell CO-Stimulator (ICOS), a critical immune checkpoint receptor expressed on activated T cells. ICOS plays a pivotal role in T-cell activation, differentiation, and effector function by delivering co-stimulatory signals following antigen recognition. Upon binding to its ligand ICOSL, ICOS promotes the expansion and function of various T-cell subsets, including follicular helper T cells and regulatory T cells, making it essential for adaptive immune responses. Dysregulation of ICOS signaling has been implicated in autoimmune diseases, transplant rejection, and represents an emerging target in immuno-oncology research.
Feladilimab is an investigational agonistic antibody designed to enhance anti-tumor immunity by stimulating ICOS-mediated T-cell responses. This biosimilar provides researchers with a valuable tool for investigating ICOS biology, exploring combination immunotherapy strategies, and studying T-cell co-stimulation mechanisms in various disease models. It enables detailed examination of ICOS pathway modulation in preclinical studies and supports the development of novel therapeutic approaches targeting immune checkpoint pathways.
There are currently no reviews for this product.